|Bid||0.00 x 800|
|Ask||0.00 x 1200|
|Day's Range||18.77 - 19.66|
|52 Week Range||11.64 - 19.66|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar. 01, 2021|
|Forward Dividend & Yield||2.20 (11.83%)|
|Ex-Dividend Date||Dec. 15, 2020|
|1y Target Est||19.31|
Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to reduce the burden of chronic injections for people with rare diseases, as evidenced by its recent phased launch of MYCAPSSA® as the first oral therapy for treatment of acromegaly, today announced that Mark Fitzpatrick intends to step down as President and Principal Financial Officer. The company plans to initiate an executive search to identify Mr. Fitzpatrick’s successor.
FSKR Lawsuit Update - The Securities Law Firm of Menzer & Hill is filing dozens of FINRA Arbitration Claims against Broker-Dealers that sold FSKR
National investment fraud law firm, KlaymanToskes ("KT"), continues its investigation into full-service brokerage firms for the unsuitable recommendations to purchase non-traded Business Development Companies ("BDCs") including: FS Investment Corp II ("FSIC II"), FS Investment Corp III ("FSIC III"), FS Investment Corp IV ("FSIC IV"), and Corporate Capital Trust ("CCTII"). These four BDCs merged into the Franklin Square KKR Capital II Fund (NYSE:FSKR) on December 18, 2019. On June 17, 2020, FSKR announced the listing on the NYSE. These investments, and other non-traded BDCs, may have been marketed and sold to investors who were risk averse, such as retirees or other conservative investors, that were seeking income and capital preservation and were not explained the potential risks.